Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib - 100098

Spotlight
Video

Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib

kidneycancer has 684 videos Subscribe Here

Loading........
Description: Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK discusses Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.
Shared By : kidneycancer
Posted on : 11/05/18
Added : 7 months ago
Category : Kidney Cancer